|
1
|
Tiedemann RE, Gonzalez-Paz N, Kyle RA,
Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling
RP, Gertz MA, Henderson K, et al: Genetic aberrations and survival
in plasma cell leukemia. Leukemia. 22:1044–1052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernández de Larrea C, Kyle RA, Durie BG,
Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O,
Sonneveld P, et al: Plasma cell leukemia: Consensus statement on
diagnostic requirements, response criteria and treatment
recommendations by the International Myeloma Working Group.
Leukemia. 27:780–791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kyle RA, Remstein ED, Therneau TM,
Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF,
Jelinek DF, Fonseca R, et al: Clinical course and prognosis of
smoldering (asymptomatic) multiple myeloma. N Engl J Med.
356:2582–2590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fonseca R, Barlogie B, Bataille R, Bastard
C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR,
et al: Genetics and cytogenetics of multiple myeloma: A workshop
report. Cancer Res. 64:1546–1558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Avet-Loiseau H, Attal M, Moreau P,
Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M,
Yakoub-Agha I, Garderet L, et al: Genetic abnormalities and
survival in multiple myeloma: The experience of the intergroupe
francophone du myelome. Blood. 109:3489–3495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferretti E, De Smaele E, Miele E, Laneve
P, Po A, Pelloni M, Paganelli A, Di Marcotullio L, Caffarelli E,
Screpanti I, et al: Concerted microRNA control of Hedgehog
signalling in cerebellar neuronal progenitor and tumour cells. EMBO
J. 27:2616–2627. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Veigaard C and Kjeldsen E: Exploring the
genome-wide relation between copy number status and microRNA
expression. Genomics. 104:271–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao L, Xie B, Yang X, Liang H, Jiang X,
Zhang D, Xue P, Chen D and Shao Z: MiR-324-5p suppresses
hepatocellular carcinoma cell invasion by counteracting ECM
degradation through post-transcriptionally downregulating ETS1 and
SP1. PLoS One. 10:e01330742015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lub S, Maes K, Menu E, De Bruyne E,
Vanderkerken K and Van Valckenborgh E: Novel strategies to target
the ubiquitin proteasome system in multiple myeloma. Oncotarget.
7:6521–6537. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee EK and Diehl JA: SCFs in the new
millennium. Oncogene. 33:2011–2018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lau AW, Fukushima H and Wei W: The Fbw7
and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.
Front Biosci (Landmark Ed). 17:2197–2212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Maitra A and Wang H: The emerging
roles of F-box proteins in pancreatic tumorigenesis. Semin Cancer
Biol. 36:88–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uddin S, Bhat AA, Krishnankutty R, Mir F,
Kulinski M and Mohammad RM: Involvement of F-BOX proteins in
progression and development of human malignancies. Semin Cancer
Biol. 36:18–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma R, Williams PJ, Gupta A, McCluskey
B, Bhaskaran S, Muñoz S and Oyajobi BO: A dominant-negative F-box
deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly
reduces myeloma cell growth and survival in mice. Oncotarget.
6:21589–21602. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bompard G, Sharp SJ, Freiss G and Machesky
LM: Involvement of Rac in actin cytoskeleton rearrangements induced
by MIM-B. J Cell Sci. 118:5393–5403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma S, Guan XY, Lee TK and Chan KW:
Clinicopathological significance of missing in metastasis B
expression in hepatocellular carcinoma. Hum Pathol. 38:1201–1206.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parr C and Jiang WG: Metastasis suppressor
1 (MTSS1) demonstrates prognostic value and anti-metastatic
properties in breast cancer. Eur J Cancer. 45:1673–1683. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Du P, Ye L, Ruge F, Yang Y and Jiang WG:
Metastasis suppressor-1, MTSS1, acts as a putative tumour
suppressor in human bladder cancer. Anticancer Res. 31:3205–3212.
2011.PubMed/NCBI
|
|
19
|
Yu D, Zhan XH, Zhao XF, Williams MS, Carey
GB, Smith E, Scott D, Zhu J, Guo Y, Cherukuri S, et al: Mice
deficient in MIM expression are predisposed to lymphomagenesis.
Oncogene. 31:3561–3568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schemionek M, Kharabi Masouleh B, Klaile
Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B,
Hiddemann W, et al: Identification of the adapter molecule MTSS1 as
a potential oncogene-specific tumor suppressor in acute myeloid
leukemia. PLoS One. 10:e01257832015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schemionek M, Herrmann O, Reher MM,
Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler
S, Braunschweig T, et al: MTSS1 is a critical epigenetically
regulated tumor suppressor in CML. Leukemia. 30:823–832. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong J, Shaik S, Wan L, Tron AE, Wang Z,
Sun L, Inuzuka H and Wei W: SCF β-TRCP targets MTSS1 for
ubiquitination-mediated destruction to regulate cancer cell
proliferation and migration. Oncotarget. 4:2339–2353. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised International Staging System
for Multiple Myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan H, Wu QL, Sun CY, Ai LS, Deng J, Zhang
L, Chen L, Chu ZB, Tang B, Wang K, et al: piRNA-823 contributes to
tumorigenesis by regulating de novo DNA methylation and
angiogenesis in multiple myeloma. Leukemia. 29:196–206. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai
LS, Zhang L and Hu Y: miR-15a and miR-16 affect the angiogenesis of
multiple myeloma by targeting VEGF. Carcinogenesis. 34:426–435.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang W, Su G, Li J, Liao J, Chen S, Huang
C, Liu F, Chen Q and Ye Y: Enhanced anti-colorectal cancer effects
of carfilzomib combined with CPT-11 via downregulation of nuclear
f7actor-κB in vitro and in vivo. Int J Oncol. 45:995–1010. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rajan AM and Rajkumar SV: Interpretation
of cytogenetic results in multiple myeloma for clinical practice.
Blood Cancer J. 5:e3652015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boyd KD, Ross FM, Chiecchio L, Dagrada GP,
Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ,
et al: A novel prognostic model in myeloma based on co-segregating
adverse FISH lesions and the ISS: Analysis of patients treated in
the MRC myeloma IX trial. Leukemia. 26:349–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Drach J, Ackermann J, Fritz E, Krömer E,
Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, et
al: Presence of a p53 gene deletion in patients with multiple
myeloma predicts for short survival after conventional-dose
chemotherapy. Blood. 92:802–809. 1998.PubMed/NCBI
|
|
31
|
Manasanch EE, Korde N, Zingone A, Tageja
N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M and
Landgren O: The proteasome: Mechanisms of biology and markers of
activity and response to treatment in multiple myeloma. Leuk
Lymphoma. 55:1707–1714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deshaies RJ: Proteotoxic crisis, the
ubiquitin-proteasome system, and cancer therapy. BMC Biol.
12:942014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ang XL and Wade Harper J: SCF-mediated
protein degradation and cell cycle control. Oncogene. 24:2860–2870.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS and
Bae I: β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR
inhibitors in triple-negative breast cancer cells. Exp Mol Med.
47:e1432015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang S and Qi Q: MTSS1 suppresses cell
migration and invasion by targeting CTTN in glioblastoma. J
Neurooncol. 121:425–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi W, Hasimu G, Wang Y, Li N, Chen M and
Zhang H: MTSS1 is an independent prognostic biomarker for survival
in intrahepatic cholangiocarcinoma patients. Am J Transl Res.
7:1974–1983. 2015.PubMed/NCBI
|
